TenSixteen Bio

TenSixteen Bio is the first company to leverage somatic chimerism and clonal hematopoiesis (CHIP) to discover and develop new therapies for age-related diseases. As a company incubated by Foresite Labs, TenSixteen Bio evaluates how the DNA in our cells changes throughout our lives, building datasets to measure, understand, and harness this evolution to inform drug discovery. The company aims to utilize its genomic and clinical platforms to address a range of age-related diseases, including cancer and cardiovascular conditions.